New vaccine aims to stop deadly diarrhea in kids
NCT ID NCT07666750
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new vaccine (IP-QSV) designed to protect against four types of Shigella bacteria, which cause severe diarrhea. The trial will include 370 healthy adults, children, and infants in Mali. Researchers will check if the vaccine is safe and triggers a strong immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Quadrivalent Shigella vaccine (IP-QSV) – a shot that targets four types of Shigella bacteria
- What this could lead to
- If successful, this could lead to a vaccine that protects against Shigella infection, a major cause of severe diarrhea in children.
- What could go wrong
- This is an early (Phase 1/2a) study, so the vaccine may not prove safe or effective. Results are limited to a specific region and may not apply elsewhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLA INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.